Recent progress in the use and tracking of transplanted islets as a personalized treatment for type 1 diabetes

Genaro A. Paredes-Juarez, Paul de Vos, Jeff W Bulte

Research output: Contribution to journalReview article

Abstract

Introduction: Type 1 diabetes mellitus (T1DM) is an autoimmune disease in which the pancreas produces insufficient amounts of insulin. T1DM patients require exogenous sources of insulin to maintain euglycemia. Transplantation of naked or microencapsulated pancreatic islets represents an alternative paradigm to obtain an autonomous regulation of blood glucose levels in a controlled and personalized fashion. However, once transplanted, the fate of these personalized cellular therapeutics is largely unknown, justifying the development of non-invasive tracking techniques. Areas covered: In vivo imaging of naked pancreatic islet transplantation, monitoring of microencapsulated islet transplantation, visualizing pancreatic inflammation, imaging of molecular-genetic therapeutics, imaging of beta cell function. Expert commentary: There are still several hurdles to overcome before (microencapsulated) islet cell transplantation will become a mainstay therapy. Non-invasive imaging methods that can track graft volume, graft rejection, graft function (insulin secretion), microcapsule engraftment, microcapsule rupture, and pancreatic inflammation are currently being developed to design the best experimental transplantation paradigms.

Original languageEnglish (US)
Pages (from-to)57-67
Number of pages11
JournalExpert Review of Precision Medicine and Drug Development
Volume2
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Islets of Langerhans Transplantation
Type 1 Diabetes Mellitus
Insulin
Islets of Langerhans
Capsules
Transplantation
Inflammation
Transplants
Cell Transplantation
Graft Rejection
Autoimmune Diseases
Blood Glucose
Molecular Biology
Rupture
Pancreas
Research Design
Therapeutics

Keywords

  • Diabetes
  • Imaging
  • Inflammation
  • Insulin
  • Islet cells
  • Microencapsulation
  • Personalized medicine
  • Transplantation

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Recent progress in the use and tracking of transplanted islets as a personalized treatment for type 1 diabetes. / Paredes-Juarez, Genaro A.; de Vos, Paul; Bulte, Jeff W.

In: Expert Review of Precision Medicine and Drug Development, Vol. 2, No. 1, 01.01.2017, p. 57-67.

Research output: Contribution to journalReview article

@article{a944390967444fd0b4b8429d33dae909,
title = "Recent progress in the use and tracking of transplanted islets as a personalized treatment for type 1 diabetes",
abstract = "Introduction: Type 1 diabetes mellitus (T1DM) is an autoimmune disease in which the pancreas produces insufficient amounts of insulin. T1DM patients require exogenous sources of insulin to maintain euglycemia. Transplantation of naked or microencapsulated pancreatic islets represents an alternative paradigm to obtain an autonomous regulation of blood glucose levels in a controlled and personalized fashion. However, once transplanted, the fate of these personalized cellular therapeutics is largely unknown, justifying the development of non-invasive tracking techniques. Areas covered: In vivo imaging of naked pancreatic islet transplantation, monitoring of microencapsulated islet transplantation, visualizing pancreatic inflammation, imaging of molecular-genetic therapeutics, imaging of beta cell function. Expert commentary: There are still several hurdles to overcome before (microencapsulated) islet cell transplantation will become a mainstay therapy. Non-invasive imaging methods that can track graft volume, graft rejection, graft function (insulin secretion), microcapsule engraftment, microcapsule rupture, and pancreatic inflammation are currently being developed to design the best experimental transplantation paradigms.",
keywords = "Diabetes, Imaging, Inflammation, Insulin, Islet cells, Microencapsulation, Personalized medicine, Transplantation",
author = "Paredes-Juarez, {Genaro A.} and {de Vos}, Paul and Bulte, {Jeff W}",
year = "2017",
month = "1",
day = "1",
doi = "10.1080/23808993.2017.1302305",
language = "English (US)",
volume = "2",
pages = "57--67",
journal = "Expert Review of Precision Medicine and Drug Development",
issn = "2380-8993",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

TY - JOUR

T1 - Recent progress in the use and tracking of transplanted islets as a personalized treatment for type 1 diabetes

AU - Paredes-Juarez, Genaro A.

AU - de Vos, Paul

AU - Bulte, Jeff W

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Introduction: Type 1 diabetes mellitus (T1DM) is an autoimmune disease in which the pancreas produces insufficient amounts of insulin. T1DM patients require exogenous sources of insulin to maintain euglycemia. Transplantation of naked or microencapsulated pancreatic islets represents an alternative paradigm to obtain an autonomous regulation of blood glucose levels in a controlled and personalized fashion. However, once transplanted, the fate of these personalized cellular therapeutics is largely unknown, justifying the development of non-invasive tracking techniques. Areas covered: In vivo imaging of naked pancreatic islet transplantation, monitoring of microencapsulated islet transplantation, visualizing pancreatic inflammation, imaging of molecular-genetic therapeutics, imaging of beta cell function. Expert commentary: There are still several hurdles to overcome before (microencapsulated) islet cell transplantation will become a mainstay therapy. Non-invasive imaging methods that can track graft volume, graft rejection, graft function (insulin secretion), microcapsule engraftment, microcapsule rupture, and pancreatic inflammation are currently being developed to design the best experimental transplantation paradigms.

AB - Introduction: Type 1 diabetes mellitus (T1DM) is an autoimmune disease in which the pancreas produces insufficient amounts of insulin. T1DM patients require exogenous sources of insulin to maintain euglycemia. Transplantation of naked or microencapsulated pancreatic islets represents an alternative paradigm to obtain an autonomous regulation of blood glucose levels in a controlled and personalized fashion. However, once transplanted, the fate of these personalized cellular therapeutics is largely unknown, justifying the development of non-invasive tracking techniques. Areas covered: In vivo imaging of naked pancreatic islet transplantation, monitoring of microencapsulated islet transplantation, visualizing pancreatic inflammation, imaging of molecular-genetic therapeutics, imaging of beta cell function. Expert commentary: There are still several hurdles to overcome before (microencapsulated) islet cell transplantation will become a mainstay therapy. Non-invasive imaging methods that can track graft volume, graft rejection, graft function (insulin secretion), microcapsule engraftment, microcapsule rupture, and pancreatic inflammation are currently being developed to design the best experimental transplantation paradigms.

KW - Diabetes

KW - Imaging

KW - Inflammation

KW - Insulin

KW - Islet cells

KW - Microencapsulation

KW - Personalized medicine

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=85053759068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053759068&partnerID=8YFLogxK

U2 - 10.1080/23808993.2017.1302305

DO - 10.1080/23808993.2017.1302305

M3 - Review article

C2 - 29276781

AN - SCOPUS:85053759068

VL - 2

SP - 57

EP - 67

JO - Expert Review of Precision Medicine and Drug Development

JF - Expert Review of Precision Medicine and Drug Development

SN - 2380-8993

IS - 1

ER -